PRINCETON, N.J., Oct. 4 /PRNewswire/ — Novo Nordisk, a global
healthcare company and leader in diabetes care, today announced a
$73 million expansion of its Clayton, NC manufacturing facility to
accommodate increased production capacity for the Company’s insulin
delivery devices.
The initial expansion will create 205 new jobs, including 85 in
the Novo Nordisk Clayton facility, which currently produces a
number of products, including the Levemir® FlexPen®
(insulin detemir [rDNA origin] injection) and other products for
the entire diabetes portfolio. Novo Nordisk currently has more than
420 employees in Clayton who oversee the full production process
for six different diabetes treatment products, from formulation
through packaging and distribution. The expansion will include the
addition of two final assembly lines, two packing lines and
building refurbishment.
“The investment to expand our Clayton facility is another
example of our commitment to improving diabetes treatment options
in the U.S. by ensuring patients have access to the latest advances
in treatment,” said Jerzy Gruhn, president of Novo Nordisk Inc.
“Insulin delivery devices give people with diabetes a convenient
way to manage their health and engage in a productive lifestyle. As
patients in the U.S. continue to move from administering insulin
with a conventional vial and syringe to using a pen device, Novo
Nordisk will be prepared to meet growing market demand.”
Novo Nordisk, which created the first insulin pen device in
1985, is a world leader in producing and delivering innovative
insulin delivery systems. The company has been working with
physicians and patients to demonstrate the many benefits of modern
delivery devices over vials and syringes, including adherence, ease
of use and dosing accuracy. Since their launch 25 years ago,
devices have become the dominant form of insulin delivery in most
markets outside the U.S. and are gaining share domestically.
Novo
‘/>”/>
